compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen’s wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib
Company profile
Ticker
CGEN
Exchange
Website
CEO
Anat Cohen-Dayag
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CGEN stock data
Latest filings (excl ownership)
20-F
2023 FY
Annual report (foreign)
5 Mar 24
6-K
Compugen Reports Fourth Quarter and Full Year 2023 Results
5 Mar 24
6-K
Compugen Announces Appointment of
15 Feb 24
6-K
Current report (foreign)
8 Jan 24
6-K
Current report (foreign)
19 Dec 23
6-K
Compugen Reports Third Quarter 2023 Results
7 Nov 23
6-K
Current report (foreign)
6 Nov 23
6-K
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
3 Nov 23
6-K
Current report (foreign)
21 Sep 23
UPLOAD
Letter from SEC
24 Aug 23
Transcripts
CGEN
Earnings call transcript
2023 Q4
5 Mar 24
CGEN
Earnings call transcript
2023 Q3
7 Nov 23
CGEN
Earnings call transcript
2023 Q2
7 Aug 23
CGEN
Earnings call transcript
2023 Q1
15 May 23
CGEN
Earnings call transcript
2022 Q2
5 Aug 22
CGEN
Earnings call transcript
2021 Q1
13 May 21
CGEN
Earnings call transcript
2020 Q4
25 Feb 21
CGEN
Earnings call transcript
2020 Q3
6 Nov 20
Latest ownership filings
SC 13G/A
Nikko Asset Management Americas, Inc.
10 Feb 23
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
3 Feb 23
SC 13G/A
Nikko Asset Management Americas, Inc.
14 Feb 22
SC 13G/A
ARK Investment Management LLC
9 Feb 22
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
4 Feb 22
SC 13G
BRISTOL MYERS SQUIBB CO
19 Nov 21
SC 13G/A
ARK Investment Management LLC
16 Feb 21
SC 13G/A
Nikko Asset Management Americas, Inc.
11 Feb 21
SC 13G/A
Sumitomo Mitsui Trust Holdings, Inc.
5 Feb 21
SC 13G/A
ARK Investment Management LLC
9 Oct 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
17.8% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 67 |
Opened positions | 10 |
Closed positions | 9 |
Increased positions | 16 |
Reduced positions | 15 |
13F shares | Current |
---|---|
Total value | 11.51 bn |
Total shares | 15.89 mm |
Total puts | 5.80 k |
Total calls | 16.80 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
BMY Bristol-Myers Squibb | 4.76 mm | $29.87 mm |
Taylor Frigon Capital Management | 1.99 mm | $2.27 bn |
Rock Springs Capital Management | 1.29 mm | $1.47 bn |
Sphera Funds Management | 1.23 mm | $1.40 bn |
Renaissance Technologies | 1.04 mm | $1.18 mm |
MCQEF Macquarie | 852.94 k | $972.00 mm |
MS Morgan Stanley | 778.38 k | $887.35 mm |
Antonetti Capital Management | 775.08 k | $883.59 mm |
Two Sigma Investments | 393.29 k | $448.35 mm |
Two Sigma Advisers | 372.58 k | $424.75 mm |
Press releases
Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503
10 Apr 24
Compugen to Participate in Two Upcoming Investor Conferences
3 Apr 24
Compugen Selected for two Oral Presentations at the Keystone Symposium on Cancer Immunotherapy
11 Mar 24
Compugen to Present Data Reflecting its Diversified Immuno-Oncology Pipeline at AACR 2024
6 Mar 24
Compugen Reports Fourth Quarter and Full Year 2023 Results
5 Mar 24